Skip to main content

Advertisement

Log in

Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Whether monoallelic MUTYH mutations increase female breast cancer risk remains controversial. This study aimed to determine if monoallelic MUTYH mutations are associated with increased breast cancer risk in women undergoing multigene panel testing (MGPT). The prevalence of monoallelic MUTYH mutations was compared between Non-Hispanic white female breast cancer cases (n = 30,456) and cancer-free controls (n = 12,289), all of whom underwent MGPT that included MUTYH. We tested breast cancer associations with MUTYH alleles using Fisher’s exact test, followed by multivariate logistic regression adjusted for age at testing and MGPT type ordered. Frequencies of the two most common MUTYH founder mutations, p.G396D and p.Y179C, were compared independently between the breast cancer cases and MGPT controls, as well as the healthy UK10K control population (n = 2640). Comparing cases to MGPT controls, no association was observed between female breast cancer and any monoallelic MUTYH carrier status (OR 0.86–1.36, p = 0.21–0.96). Similarly, comparisons to UK10K controls revealed no significant increase in breast cancer risk associated with p.G396D (OR 1.20, p = 0.44) or p.Y179C (OR 1.71, p = 0.24). This study did not find a significant increase in breast cancer risk associated with monoallelic MUTYH mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136:1251–1260

    Article  CAS  PubMed  Google Scholar 

  2. Lubbe SJ, Di Bernardo MC, Chandler IP et al (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27:3975–3980

    Article  CAS  PubMed  Google Scholar 

  3. Theodoratou E, Campbell H, Tenesa A et al (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Win AK, Dowty JG, Cleary SP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208–1211.e1–5

    Article  CAS  PubMed  Google Scholar 

  5. Vogt S, Jones N, Christian D et al (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–85.e10

    Article  CAS  PubMed  Google Scholar 

  6. Kanter-Smoler G, Björk J, Fritzell K et al (2006) Novel findings in Swedish patients with MYH-associated polyposis: mutation detection and clinical characterization. Clin Gastroenterol Hepatol 4:499–506

    Article  CAS  PubMed  Google Scholar 

  7. Sieber OM, Lipton L, Crabtree M et al (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791–799

    Article  PubMed  Google Scholar 

  8. Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10:1–9

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rennert G, Lejbkowicz F, Cohen I et al (2012) MutYH mutation carriers have increased breast cancer risk. Cancer 118:1989–1993

    Article  CAS  PubMed  Google Scholar 

  10. Zhu M, Chen X, Zhang H et al (2011) AluYb8 insertion in the MUTYH gene and risk of early-onset breast and gastric cancers in the Chinese population. Asian Pac J Cancer Prev 12:1451–1455

    PubMed  Google Scholar 

  11. Beiner M, Zhang W, Zhang S et al (2009) Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Res Treat 114:575–578

    Article  CAS  PubMed  Google Scholar 

  12. Out AA, Wasielewski M, Huijts PE et al (2012) MUTYH gene variants and breast cancer in a Dutch case-control study. Breast Cancer Res Treat 134:219–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Win AK, Reece JC, Dowty JG et al (2016) Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer 139:1557–1563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. UK10K Consortium, Walter K, Min JL et al (2015) The UK10K project identifies rare variants in health and disease. Nature 526:82–90

    Article  CAS  Google Scholar 

  15. LaDuca H, Stuenkel AJ, Dolinsky JS et al (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 16(11):830–837

    Article  PubMed  PubMed Central  Google Scholar 

  16. Pesaran T, Karam R, Huether R et al (2016) Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes. Int J Breast Cancer. https://doi.org/10.1155/2016/2469523

    Article  PubMed  PubMed Central  Google Scholar 

  17. Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424

    Article  PubMed  PubMed Central  Google Scholar 

  18. Win AK, Cleary SP, Dowty JG et al (2011) Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129:2256–2262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Horton C, LaDuca H, McFarland R et al (2017) In laboratory clinical data we trust? Accuracy and completeness of test requisition form data in a cohort of ovarian and uterine cancer patients referred for clinical genetic testing. In: 48th annual conference of the society of gynecologic oncology; March 12–15; National Harbor, MD

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kelly Fulk.

Ethics declarations

Conflict of interest

C.E. was a full-time salaried employee of Ambry Genetics during the time she worked on this study and is currently a full-time salaried employee of Guardant Health. All other authors are currently full-time salaried employees of Ambry Genetics.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fulk, K., LaDuca, H., Black, M.H. et al. Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort. Familial Cancer 18, 197–201 (2019). https://doi.org/10.1007/s10689-018-00114-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-018-00114-4

Keywords

Navigation